Aitmyte 100 RI + 300 RI Resoriblett, sublingual Svédország - svéd - Läkemedelsverket (Medical Products Agency)

aitmyte 100 ri + 300 ri resoriblett, sublingual

stallergenes - allergen, husdammskvalster dermatophagoides farinae; allergen, husdammskvalster dermatophagoides pteronyssinus - resoriblett, sublingual - 100 ri + 300 ri - allergen, husdammskvalster dermatophagoides pteronyssinus 50 e aktiv substans; allergen, husdammskvalster dermatophagoides farinae 50 e aktiv substans; laktosmonohydrat hjälpämne; allergen, husdammskvalster dermatophagoides pteronyssinus 150 e aktiv substans; mannitol hjälpämne; allergen, husdammskvalster dermatophagoides farinae 150 e aktiv substans; laktosmonohydrat hjälpämne

Ultomiris Európai Unió - svéd - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektiva immunsuppressiva medel - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Kaliumjodid G.L. Pharma 65 mg Tablett Svédország - svéd - Läkemedelsverket (Medical Products Agency)

kaliumjodid g.l. pharma 65 mg tablett

g.l. pharma gmbh - kaliumjodid - tablett - 65 mg - kaliumjodid 65 mg aktiv substans; laktosmonohydrat hjälpämne - kaliumjodid

Phenichem 18 mg Depottablett Svédország - svéd - Läkemedelsverket (Medical Products Agency)

phenichem 18 mg depottablett

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 18 mg - laktosmonohydrat hjälpämne; metylfenidathydroklorid 3,24 mg aktiv substans; metylfenidathydroklorid 14,76 mg aktiv substans

Phenichem 27 mg Depottablett Svédország - svéd - Läkemedelsverket (Medical Products Agency)

phenichem 27 mg depottablett

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 27 mg - laktosmonohydrat hjälpämne; metylfenidathydroklorid 4,86 mg aktiv substans; metylfenidathydroklorid 22,14 mg aktiv substans

Phenichem 36 mg Depottablett Svédország - svéd - Läkemedelsverket (Medical Products Agency)

phenichem 36 mg depottablett

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 36 mg - metylfenidathydroklorid 29,52 mg aktiv substans; laktosmonohydrat hjälpämne; metylfenidathydroklorid 6,48 mg aktiv substans

Phenichem 54 mg Depottablett Svédország - svéd - Läkemedelsverket (Medical Products Agency)

phenichem 54 mg depottablett

laboratorios liconsa s.a. - metylfenidathydroklorid - depottablett - 54 mg - metylfenidathydroklorid 44,28 mg aktiv substans; laktosmonohydrat hjälpämne; metylfenidathydroklorid 9,72 mg aktiv substans

Eptifibatide Mylan 0,75 mg/ml Infusionsvätska, lösning Svédország - svéd - Läkemedelsverket (Medical Products Agency)

eptifibatide mylan 0,75 mg/ml infusionsvätska, lösning

mylan hospital as - eptifibatid - infusionsvätska, lösning - 0,75 mg/ml - eptifibatid 0,75 mg aktiv substans - eptifibatid

Eptifibatide Mylan 2 mg/ml Injektionsvätska, lösning Svédország - svéd - Läkemedelsverket (Medical Products Agency)

eptifibatide mylan 2 mg/ml injektionsvätska, lösning

mylan hospital as - eptifibatid - injektionsvätska, lösning - 2 mg/ml - eptifibatid 2 mg aktiv substans - eptifibatid

Velos 10 mg Injektionsvätska, lösning i förfylld spruta Svédország - svéd - Läkemedelsverket (Medical Products Agency)

velos 10 mg injektionsvätska, lösning i förfylld spruta

difa cooper s.p.a. - metotrexat - injektionsvätska, lösning i förfylld spruta - 10 mg - metotrexat 10 mg aktiv substans - metotrexat